Akèy › Kasinòm epitelyal ovè › Maryland
Etid klinik pou Kasinòm epitelyal ovè nan Maryland
7 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Oct 1, 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Maryland, Baltimore /ID# 275308, Baltimore
- Holy Cross Hospital /ID# 275872, Silver Spring
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Towson
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Greater Baltimore Medical Center, Towson
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Maryland Oncology Hematology, P.A., Annapolis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- Anne Arundel Health System, Annapolis
- Johns Hopkins University School of Medicine, Baltimore
Ap rekriteEtid obsèvasyon
Laj 30 ak plis · Fanm · Mizajou Sep 16, 2025 · NCT04794322BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 7, 2025 · NCT04196257Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.